logo

Alexion Pharmaceuticals Inc. (ALXN)



Trade ALXN now with
  Date
  Headline
9/14/2020 8:03:37 AM Alexion And Caelum Biosciences Announce Initiation Of CARES Phase 3 Clinical Program To Evaluate CAEL-101
8/6/2020 8:03:13 AM Alexion Appoints Uzair Qadeer As First Chief Diversity Officer
7/30/2020 6:34:30 AM Alexion Q2 Loss/Shr $4.84 Vs EPS $2.04 Last Year
7/2/2020 8:47:09 AM ALEXION Announces Successful Completion Of Acquisition Of Portola Pharmaceuticals
6/29/2020 2:15:56 AM Alexion : ULTOMIRIS Gets Marketing Authorization From EU For Adults And Children With Atypical Hemolytic Uremic Syndrome
6/24/2020 9:15:30 AM Alexion Says Phase 3 Study Of Weekly Subcutaneous ULTOMIRIS Met Primary Endpoint
5/14/2020 9:38:14 AM Alexion Says Five Abstracts Accepted For Presentation At The 25th Congress Of EHA
5/6/2020 6:50:14 AM Alexion Pharmaceuticals Inc. (ALXN) Has Lowered Its FY20 Revenue Estimate To $5,230 - $5,330 Mln From $5,500 - $5,560 Mln
5/6/2020 6:49:20 AM Alexion Pharmaceuticals Inc. (ALXN) Has Lowered Its FY20 EPS Estimate To 10.45 - 10.75 From 10.65 - 10.85
5/6/2020 6:34:42 AM Alexion Pharmaceuticals Q1 GAAP EPS Down 4% To $2.50